OS Therapies Incorporated filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission on September 10, 2026. The filing details the filing of a prospectus supplement related to the resale of the company's common stock.
The prospectus supplement covers the resale from time to time of up to 5,874,094 shares of the Company’s common stock by selling stockholders. These shares are referenced in the prospectus supplement, which forms a part of the Company’s registration statement on Form S-3 (File No. 333-289443).
The registration statement on Form S-3 was originally filed with the SEC on August 8, 2025, and was declared effective on August 25, 2025. The filing is intended to provide the legal opinion of the Company’s counsel, Olshan Frome Wolosky LLP, regarding the legality of the Shares. This legal opinion is attached as Exhibit 5.1 to the Current Report.
The Company’s principal executive offices are located at 115 Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638.
